Annual review

2022 was an eventful year for the Zur Rose Group. The overview below provides key insights of the most important developments and related background information.

Chairman of the Board Walter Oberhänsli and CEO Walter Hess look back on the year 2022

At a glance

The Zur Rose Group in 2022 in facts and figures.

Read more

The DocMorris app and e-scripts in Germany

The national roll-out of e-prescriptions in Germany started in September 2022. Find out more about the background and opportunities in this key step in digitalisation. In addition, learn more about the DocMorris healthcare app and its services.

Read more

Letter to Shareholders

The Zur Rose Group achieved its targets set for 2022: external revenue amounted to CHF 1,836.7 million. Thanks to the consistent implementation of the break-even programme, adjusted EBITDA improved significantly by CHF 59.2 million.

Read more

This site uses cookies to optimise the functions of the website and to ensure you enjoy the best possible experience. For more information, please see our cookie statement.